To decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen
For extensive-stage small cell lung cancer (ES-SCLC)
SPARE THE MARROW. SPEAR THE TUMOR.
COSELA HELPS PROTECT AGAINST myelosuppression, while chemotherapy targets cancer cells
COSELA® (trilaciclib) helps protect hematopoietic stem and progenitor cells (HSPCs), the source of blood cell lineages, including neutrophils, red blood cells, and platelets
The First and Only Proactive Multilineage Myeloprotection Therapy
In the Pivotal Study in 1st-Line ES-SCLC, COSELA administered before an etoposide/carboplatin + atezolizumab (E/P/A) regimen resulted in1:
REDUCED INCIDENCE AND DURATION OF SEVERE NEUTROPENIA
Primary Endpoints: 1.9% vs 49.1% (P<0.0001) and 0 days vs 4 days (P<0.0001) with and without COSELA, respectively*
NUMERICALLY LOWERED INCIDENCE OF GRADE 3/4 ANEMIA AND RBC TRANSFUSIONS
Secondary Endpoints: 19% vs 28% and 13% vs 21% with and without COSELA, respectively†
REDUCED INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA
Secondary Endpoint: 1.9% vs 37.7% with and without COSELA (P=0.0026)‡
REDUCED RATE OF CHEMOTHERAPY DOSE REDUCTIONS
Secondary Endpoint: 2.1 vs 8.5 with and without COSELA (P=0.0195)§
|*||Multiplicity-adjusted P values. Adjusted relative risk (aRR) 0.038 (95% CI, 0.008, 0.195) and mean difference -3.6 (95% CI, -4.9, -2.3), respectively. Duration evaluated in Cycle 1.|
|†||aRR 0.663 (95% CI, 0.336, 1.310) and aRR 0.642 (95% CI, 0.294, 1.404). Red blood cell (RBC) transfusions measured on/after 5 weeks. Grade 3/4 anemia defined as Grade 3/4 decreased hemoglobin.|
|‡||Raw one-sided P value not adjusted for multiplicity. aRR 0.053 (95% CI, 0.008, 0.356). Platelet endpoint results were not consistent across studies. See Study 2. See Study 3.|
|§||Raw one-sided P value not adjusted for multiplicity. Rate of all-cause dose reductions, events per 100 cycles. aRR 0.242 (95% CI, 0.079, 0.742).|
Standard-of-care supportive interventions, including RBC and platelet transfusions, were allowed per investigator discretion throughout the entire treatment period. Primary prophylaxis with granulocyte colony-stimulating factors (G-CSFs) and use of erythropoiesis stimulating agents (ESAs) were prohibited in Cycle 1 of induction, although therapeutic G-CSF was allowed in all cycles. More patients in the E/P/A regimen arm without COSELA received G-CSF Administration (47.2% vs 29.6%, aRR 0.646 [95% CI, 0.403, 1.034]) and had ESA use (11% vs 6%, aRR 0.529 [95% CI, 0.145, 1.927]) vs with COSELA, respectively.
THE FIRST & ONLY MYELOPROTECTION THERAPY
COSELA helps protect hematopoietic stem and progenitor cells (HSPCs), the source of multiple blood cell lineages, including neutrophils, red blood cells, and platelets. Watch the COSELA mechanism of action (MOA) video to learn about the proactive and multilineage MOA.
Additionally, find key insights from a leading medical oncologist.Explore the MOA >